Words by Jade Williams
Genentech, a subsidiary of Roche, has laid down $850m for Regor Pharmaceuticals’ portfolio of next-generation CDK inhibitors for the treatment of breast cancer. The deal positions Genentech to lead the global development and commercialisation of these promising therapeutics.
While Genentech will assume responsibility for the clinical development, manufacturing and worldwide commercialisation of the inhibitors, Regor, a Chinese American biotech, will continue overseeing the two ongoing Phase 1 clinical trials for the products until their completion.
The company will also maintain its focus on advancing other assets in its pipeline, including therapies in oncology, metabolic diseases and auto-immune disorders, which remain unaffected by the transaction.
“Genentech is well-positioned to bring these novel therapeutics to their full potential to benefit patients with breast cancer around the world,” commented Xiayang Qiu, Founder and CEO, Regor Pharmaceuticals. “We are proud of the strong data we have generated to date. We look forward to bringing more innovative therapies to patients around the world.”
The acquisition is expected to be finalised by Q4 2024, subject to customary closing conditions. This transaction marks another major step in expanding targeted therapies for breast cancer, shedding light on the growing interest in next-generation inhibitor technology within the industry.
